Theme
Biotech '25: Oncology & Immunotherapy☆

ACLX-22.05%8.3%

AVBP+50.13%8.3%

CGEM+169.74%8.3%

CRSP-23.85%8.3%

JANX-24.37%8.3%

NRIX+155.23%8.3%

NUVB+41.24%8.3%

NUVL0.00%8.3%

PTGX+117.64%8.3%

RIGL+62.70%8.3%

RVMD+347.90%8.3%

ZYME+53.85%8.3%
As of Oct 2, 2026, 9:55 PM ET
Biotech '25: Oncology & Immunotherapy Constituents
Arcellx, Inc.ACLX | 8.3% | 0.00% | 0.00% | 0.00% | 0.00% | -1.67% | 0.00% | -4.64% | -22.05% | -15.87% | 281.61% | $3.75B |
ArriVent BioPharma, Inc.AVBP | 8.3% | -2.28% | -6.76% | -7.34% | -2.28% | 40.51% | 23.07% | 57.06% | 50.13% | 10.34% | 57.06% | $1.32B |
CRISPR Therapeutics AGCRSP | 8.3% | -0.02% | -6.06% | -2.57% | 0.03% | 5.75% | -7.79% | 62.20% | -23.85% | 23.45% | -50.19% | $5.35B |
Cullinan Therapeutics, Inc.CGEM | 8.3% | 6.74% | -28.43% | -30.54% | 6.74% | 49.86% | 0.06% | 98.34% | 169.74% | -3.66% | -37.33% | $953.2M |
Janux Therapeutics, Inc.JANX | 8.3% | -0.18% | 0.92% | -10.51% | 3.95% | 27.75% | 29.54% | -37.59% | -24.37% | -61.67% | -24.28% | $1.03B |
Nurix Therapeutics, Inc.NRIX | 8.3% | -1.50% | -9.72% | -10.24% | -0.71% | 22.17% | 45.12% | 103.65% | 155.23% | 6.09% | -26.41% | $2.39B |
Nuvalent, Inc.NUVL | 8.3% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -8.83% | $1.62B |
Nuvation Bio Inc.NUVB | 8.3% | -7.55% | -14.10% | -24.39% | -5.76% | -41.52% | -11.34% | 192.74% | 41.24% | 119.66% | -48.86% | $1.78B |
Protagonist Therapeutics, Inc.PTGX | 8.3% | 0.63% | -2.51% | -3.19% | 1.61% | 61.92% | 53.59% | 193.41% | 117.64% | 215.88% | 680.28% | $9.01B |
Revolution Medicines, Inc.RVMD | 8.3% | 0.36% | 6.13% | -2.17% | -0.58% | 156.99% | 100.64% | 491.59% | 347.90% | 347.95% | 609.62% | $43.93B |
Rigel Pharmaceuticals, Inc.RIGL | 8.3% | 0.38% | -6.29% | -7.43% | -2.60% | 6.82% | 31.69% | 151.24% | 62.70% | 193.77% | 33.57% | $872.4M |
Zymeworks Inc.ZYME | 8.3% | -3.12% | -5.68% | -16.26% | 0.15% | -1.25% | 11.64% | 118.12% | 53.85% | 106.32% | -14.25% | $1.85B |
| Theme return | — | -0.55% | -6.04% | -9.41% | 0.22% | 28.55% | 26.19% | 123.74% | 75.32% | 87.99% | 168.69% | — |
| Average | 8.3% | -0.54% | -6.04% | -9.55% | 0.05% | 27.28% | 23.02% | 118.84% | 77.35% | 78.52% | 121.00% | $6.15B |
| Median | 8.3% | -0.01% | -5.87% | -7.38% | 0.00% | 14.50% | 17.36% | 101.00% | 51.99% | 16.90% | -11.54% | $1.82B |
| Std Dev | 0.0% | 3.12% | 8.48% | 9.32% | 3.02% | 47.21% | 30.84% | 133.08% | 103.56% | 116.05% | 250.05% | $11.61B |
| Min | 8.3% | -7.55% | -28.43% | -30.54% | -5.76% | -41.52% | -11.34% | -37.59% | -24.37% | -61.67% | -50.19% | $872.4M |
| Max | 8.3% | 6.74% | 6.13% | 0.00% | 6.74% | 156.99% | 100.64% | 491.59% | 347.90% | 347.95% | 680.28% | $43.93B |
| % Positive Tickers | 33.33% | 16.67% | 0.00% | 41.67% | 66.67% | 66.67% | 75.00% | 66.67% | 66.67% | 41.67% |